Novel biotin-specific monoclonal antibody and use thereof
US-2019324025-A1 · Oct 24, 2019 · US
Biotin-specific monoclonal antibody and use thereof
US12559573B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12559573-B2 |
| Application number | US-202117551732-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2021 |
| Priority date | Dec 27, 2016 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
First claim
Opening claim text (preview).
The invention claimed is: 1 . An immunogen of Formula: wherein KLH is a keyhole limpet hemocyanin. 2 . A method for producing an antibody, the method comprising the steps of a) immunizing an experimental animal with an immunogen according to claim 1 , thereby inducing B-cells producing antibodies binding to the immunogen, b) obtaining a monoclonal antibody binding to the immunogen produced by the B-cell of step (a), either via hybridoma technology or by B-cell PCR technology, c) further selecting the antibody of step (b) for binding to biotin thereby obtaining an antibody.
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
involving vitamins {or their receptors} · CPC title
- C07K16/00Primary
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title
against enzymes · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12559573B2 cover?
- The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generatio…
- Who is the assignee on this patent?
- Roche Diagnostics Operations Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).